Hagop Kantarjian: In this Ph1b trial, single agent SQ blinatumomab resulted in a high MRD-negative complete remission rate

Hagop Kantarjian, Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, shared on X:

“In this Ph1b trial, single agent SQ blinatumomab resulted in a high MRD-negative complete remission rate & an acceptable safety profile in heavily pretreated adults w/ R/R B-ALL
Elias Jabbour of MD Anderson Cancer Center”